Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gene Therapy for SCID-X1 Via Direct Intravenous Injection of Lentiviral Vector
NCT03217617Phase 2Not yet recruiting
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jun 2027
- Primary completion
- Dec 2028
- Modality
- Gene Editing, Gene Silencing, Lentiviral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of IVLV-X1 in X-linked severe combined immunodeficiency (X-SCID), sponsored by Shenzhen Geno-Immune Medical Institute. Planned start Jun 2027; status: not yet recruiting.
02
Drugs
IVLV-X1
03
Conditions
X-linked severe combined immunodeficiency (X-SCID)
Beyond the preview
Go deeper on NCT03217617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03217617.